Apitoxin, Bee Venom Therapy, Management, Aphthous Ulceration
Conditions
Brief summary
The current study evaluated the clinical effect and outcome of locally applied bee venom versus low-level laser therapy (LLLT) for the treatment of recurrent aphthous ulceration.
Detailed description
Recurrent aphthous stomatitis (RAS) is a Painful, idiopathic, and recurrent inflammatory ulceration of the oral cavity. Despite their widespread use, prolonged or frequent application may result in adverse effects such as oral candida. In recent years, low-level laser therapy (LLLT) has gained attention as an alternative treatment for RAS. Apitoxin has been used traditionally to treat a variety of conditions, such as arthritis, rheumatism, back pain, cancer, and skin diseases.
Interventions
Patients managed by Low-level laser therapy (LLLT).
DRUGApitoxin
Patients managed with 0.3% Apitoxin Gel.
Sponsors
Tanta University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
15 Years to 40 Years
Healthy volunteers
No
Inclusion criteria
* Age from 15 to 40 years old. * Both sexes. * No current or history of systemic medical problem. * Non-smoker. * Suffering from pain due to recurrent aphthous stomatitis (RAS) ulceration on the oral mucosa with the following characteristics: * Duration of 2 days or less. * The diameter ≥ 4mm * Not been subjected to any treatment modalities for at least four weeks before the beginning of the study.
Exclusion criteria
* Presence of other oral mucosal ulcers other than RAS. * Systemic disease that predisposed them to RAS (e.g., Behçet disease). * Systemic medical problems. * Pregnant, lactating, and postmenopausal patients. * Smoker patients. * Systemic or topical treatment for RAS less than four weeks before starting the study. * Any earlier experiences of laser therapy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Ulcer Surface Area | 5 days post-treatment | Ulcer Surface Area: The main outcome will be the objective measurement of the ulcer surface area. This was evaluated through photographs taken on Day 1 (baseline) and Day 5 (post-treatment). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pain Sensation | 5 days post-treatment | Subjective evaluation of pain sensation using the Visual Analog Scale (VAS). VAS (0 represents no pain while 10 represents the worst pain imaginable). Pain will be assessed on Day 1 (baseline) and Day 5 (post-treatment). |
| Effectiveness Index (EI) | 5 days post-treatment | Calculated improvement in pain sensation for each patient based on baseline and post-treatment Visual Analog Scale (VAS). Formula: (VAS baseline - VAS post-treatment) / VAS baseline × 100% |
Countries
Egypt
Outcome results
None listed